The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus

Saprina T.V.; Gudkova T.K.; Stoliarova V.A.; Martynova S.Iu.; Dudar'kova N.G.; Iaroshevskaia T.G.; Latypova V.N.

doi:https://doi.org/

Saprina T.V.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Gudkova T.K.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Stoliarova V.A.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Martynova S.Iu.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Dudar'kova N.G.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Iaroshevskaia T.G.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Latypova V.N.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus

Authors:

Saprina T.V., Gudkova T.K., Stoliarova V.A., Martynova S.Iu., Dudar'kova N.G., Iaroshevskaia T.G., Latypova V.N.

More about the authors

Journal: Problems of Endocrinology. 2012;58(5): 75‑79

Read: 629 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Saprina TV, Gudkova TK, Stoliarova VA, Martynova SIu, Dudar'kova NG, Iaroshevskaia TG, Latypova VN. The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus. Problems of Endocrinology. 2012;58(5):75‑79. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Features of comorbidity pathology in young people. Russian Journal of Preventive Medicine. 2024;(11):63-69

Modern view on the etiology of gallstone disease in children. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):59-68

Options for the surgical technique of laparoscopic sleeve gastrectomy for prevention and treatment of gastroesophageal reflux in patients with obesity. Endoscopic Surgery. 2024;(6):57-68

Application of modern methods for activation of brain functions in obese patients (literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):54-61

Comparative analysis of the state of the microvasculature of the oral mucosa in persons with metabolic syndrome in the aspect of orthopedic dental rehabilitation. Stomatology. 2024;(6-2):15-22

Relationship between metabolic syndrome components and pathology of the red border of the lips and oral mucosa. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):58-63

Chronic inflammation in case of obesity-associated diseases. Russian Journal of Preventive Medicine. 2025;(1):115-121

Identification of prognostic significant markers of early diagnosis of obesity and metabolic disorders. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):71-79

Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chronic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60

Safety assessment of bariatric surgery in the Russian Federation according to the Russian National Bariatric Registry. Endoscopic Surgery. 2025;(1):5-14

Abstract:

The optimal control of diabetes mellitus (DM) should ensure not only the achievement and maintenance of the targeted blood glucose level but also the reduction of other cardiovascular risks. Obesity is a key risk factor of the development of type 2 diabetes mellitus (DM2) and an independent risk factor of cardiovascular complications. The agonists of glucagon-like peptide-1 (GLP-1) are currently considered to be the sole hypoglycemic agents that not only effectively correct hyperglycemia but also reduce the excessive body weight. Liraglutide (Victoza, Novo Nordisk) is the first long-acting analog of human GLP-1 approved for the application in the treatment of DM2 at the early stages of the disease in the form of both mono- and combined therapy. We present the literature review of the results of randomized clinical studies and our own experience with the use of Victoza for glycemic control and correction of the body weight in the patients presenting with type 2 diabetes mellitus.

Keywords:

type 2 diabetes mellitus

obesity

GLP-1 analog

liraglutide

Victoza

Authors:

Saprina T.V.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Gudkova T.K.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Stoliarova V.A.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Martynova S.Iu.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Dudar'kova N.G.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Iaroshevskaia T.G.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Latypova V.N.

GBOU VPO "Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF, Tomsk

Close metadata

References:

IDF Diabetes Atlas, 5th Edition, 2011. http://www.idf.org/diabetesatlas/5e/the-global-burden
Turner R.C., Cull C.A., Frighi V., Holman R.R. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: prospective requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
Dedov I.I., Shestakova M.V. Viktoza (liraglutid): pervyi analog chelovecheskogo GPP-1 v lechenii sakharnogo diabeta 2-go tipa. Prakticheskoe rukovodstvo dlya vrachei. M 2010; 46.
Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab, 1995; 80: 952-957.
Shestakova M.B., Vikulova O.K. Sovremennye vozmozhnosti farmakoterapii sakharnogo diabeta 2-go tipa pri pomoshchi analogov glyukagonopodobnogo peptida-1 (GPP-1). Sakharnyi diabet, 2007; 1: 9-15.
Holst J.J. GLP-1 receptor agonists for the treatment of diabetes. Int Diabetes Monitor 2005;17(6): 11-18.
Ametov A.S. Dostizhenie dvukh tselei terapii: kontrol' glikemii i snizhenie massy tela. Rossiiskii meditsinskii zhurnal 2006; 17: 24 (363): 2.
Garber A., Henry R., Ratner R. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemia and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., Zdravkovic M., Düring M., Matthews D.R. LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., Zdravkovic M., Ravn G.M., Simó R. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009; 52: 2046-2055.
Sullivan S.D., Alfonso-Cristancho R., Conner C., Hammer M., Blonde L. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovascular Diabetology 2009; 8: 12:1-9.
Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230.
Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009; 297(1-2):137-140.
Jendle J., Nauck M.A., Matthews D.R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B.J., Garber A.J. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11(12):1163-72.